NICE shelve technology appraisal on agomelatine for depression

nhs evidence eye

The manufacturer of agomelatine (Servier) has informed NICE that it would not be making an evidence submission for the appraisal of agomelatine for the treatment of major depressive episodes.

Servier drew attention to the fact that NICE guidelines for England and Wales recommend generic selective serotonin reuptake inhibitors (SSRIs) as first-line treatment followed by a different SSRI or a better tolerated newer-generation agent as second-line treatment. The manufacturer noted that the majority of the clinical trial evidence for agomelatine was as a first-line treatment and furthermore was not against the full range of comparators in the scope. The manufacturer stated that this precluded the development of an economic case that would address the NICE decision problem and maintain the requisite level of certainty.

NICE has therefore terminated this single technology appraisal.

TA231 Depression – agomelatine: guidance (PDF). NICE, 27 Jul 2011.

Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Profile photo of Andre Tomlin

Andre Tomlin

André Tomlin is an Information Scientist with 20 years experience working in evidence-based healthcare. He's worked in the NHS, for Oxford University and since 2002 as Managing Director of Minervation Ltd, a consultancy company who do clever digital stuff for charities, universities and the public sector. Most recently André has been the driving force behind the Mental Elf and the National Elf Service; an innovative digital platform that helps professionals keep up to date with simple, clear and engaging summaries of evidence-based research. André is a Trustee at the Centre for Mental Health and an Honorary Research Fellow at University College London Division of Psychiatry. He lives in Bristol, surrounded by dogs, elflings and lots of woodland!

More posts - Website

Follow me here –